Table 2.
Identical and similar phage peptides were selected by sequential CSF IgG.
| Phage ID | Peptide | Abundance a | |
|---|---|---|---|
| Patient 1 (MS 02-24) | MS-1 CSF #1-A6b | S F G T F L W | 80% (4/5) |
| MS-1 CSF #1-B1 | E F G T F L W c | 20% (1/5) | |
| MS-1 CSF #2-C7 | E F G T F L W | 36% (4/11) | |
| MS-1 CSF #2-C9 | K F G T A L W | 27% (3/11) | |
| MS-1 CSF #2-C5 | Q F G T F L W | 27% (3/11) | |
| MS-1 CSF #2-D7 | S F G T A L W | 9% (1/11) | |
|
| |||
| Patient 2 (MS 04-3) | MS-2 CSF #1-B1 | V L N W H P F | 100% (8/8) |
| MS-2 CSF #2-C9 | V L N W H P F | 50% (1/2) | |
| MS-2 CSF #2-C6 | M F N W H P F | 50% (1/2) | |
|
| |||
| Patient 3 (MS 05-4) | MS-3 CSF #1-A1 | W G L D N P P | 33% (2/6) |
| MS-3 CSF #1-A2 | A P P H L P P | 17% (1/6) | |
| MS-3 CSF #1-E7 | A P S H P P P | 17% (1/6) | |
| MS-3 CSF #1-A6 | A P P H Q M P | 17% (1/6) | |
| MS-3 CSF #1-A12 | T Y M V P A P | 17% (1/6) | |
| MS-3 CSF #2-D9 | W G L D N P P | 56% (5/9) | |
| MS-3 CSF #2-F10 | A P A H Q I P | 11% (1/9) | |
| MS-3 CSF #2-B11 | A P A H H P P | 11% (1/9) | |
| MS-3 CSF #2-B10 | A P P H V M P | 11% (1/9) | |
| MS-3 CSF #2-C11 | G P V N M N L | 11% (1/9) | |
|
| |||
| Patient 4 (MS 05-6) | MS-4 CSF #1-E12 | F H L P W M Q | 100% (1/1) |
| MS-4 CSF#2-H4 | W Y Y K P P A | 60% (3/6) | |
| MS-4 CSF #2-D10 | K W P I I D T | 20% (1/5) | |
| MS-4 CSF #2-G9 | F H L P W M Q | 20% (1/5) | |
|
| |||
| Patient 5 (ON 05-2) | MS-5 CSF #1-E9 | c P V E L Q L Y c | 17% (1/6) |
| MS-5 CSF #1-A9 | c S Q S V AA S c | 17% (1/6) | |
| MS-5 CSF #1-E8 | c G R Q A Q Y Y c | 17% (1/6) | |
| MS-5 CSF #1-C10 | c P V G P W T N c | 17% (1/6) | |
| MS-5 CSF #1-C9 | c T V Q P Q F H c | 17% (1/6) | |
| MS-5 CSF #1-F9 | c M Q A H Q T K c | 17% (1/6) | |
| MS-5 CSF #2-F12 | c P L E L S V Y c | 60% (3/5) | |
| MS-5 CSF #2-H11 | c S H R P T T Q c | 20% (1/5) | |
| MS-5 CSF #2-C12 | c S T E G R H N c | 20% (1/5) | |
a
Positive phage were amplified, purified, and phage DNA was sequenced. Peptides are listed in order of their relative frequencies of the total clones sequenced.
b
Each phage peptide was named by panning CSF IgG (patient # and CSF #) followed by the location of the well from which the phage was initially identified. For example, peptide MS-1 CSF #1-A6 indicates that the phage was selected by CSF IgG of patient 1 and CSF 1 from well A6.
c
The identical/similar peptides were highlighted.
d
Circular peptides.